Spondyloarthritis & psoriatic arthritis
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study
Authors' conclusion
Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ-ADL arms.
Study context
- Population
- Biologic-naive patients with active r-axSpA at high risk of radiographic progression (hsCRP ≥5 mg/L and/or ≥1 syndesmophyte on spinal radiographs)78.5% male
- Participants
- 859 patients
- Comparison
- Secukinumab 150 mg or 300 mg vs adalimumab biosimilar 40 mg
- Primary endpoint
- Proportion with no radiographic progression (change from baseline in mSASSS ≤0.5)
- Follow-up
- Week 104
Methodological detailsphase IIIb, head-to-head
- Phase IIIb
- Head-to-head
Primary result
As reported in the abstract
No radiographic progression (change from baseline mSASSS ≤0.5)
Secukinumab 150 mg
66.1%
Secukinumab 300 mg
66.9%
SDZ-ADL
65.6%
Secukinumab 150 mg vs SDZ-ADL: P = not significant · Secukinumab 300 mg vs SDZ-ADL: P = not significant
Further findings
No new syndesmophytes among patients with ≥1 syndesmophyte at baseline · week 104
Mean
| Outcome | Secukinumab 150 mg | Secukinumab 300 mg | SDZ-ADL |
|---|---|---|---|
| Change from baseline in mSASSS · week 104 | 0.54 | 0.55 | 0.72 |
Safety
- No unexpected safety findings
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study. Arthritis Rheumatol. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →